The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil.
Demeter is pleased to announce that its Agrinnovation fund co-led the €25 million Series A funding round of Phagos, alongside CapAgro, Hoxton Ventures, and CapHorn, with participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.
Founded in 2021, Phagos is pioneering a new generation of treatments against bacterial diseases by harnessing bacteriophages — natural viruses that specifically target bacteria — as a sustainable alternative to antibiotics. Combining microbiology and artificial intelligence, Phagos has developed a breakthrough discovery platform capable of designing personalized, high-precision therapies.
This new funding will enable Phagos to deploy its first veterinary phage-based treatments, develop the next generation of its patented AI technology, and accelerate international expansion across Europe, Asia, and the Americas.
Phagos recently achieved a major regulatory milestone, becoming the first company authorized to market personalized phage-based veterinary drugs in the EU — a turning point in the global fight against antimicrobial resistance.